Objective: Gemcitabine in low dose in prolonged infusion is a treatment with documented activity against a variety of tumors. We here report the first randomized trial to compare standard brief and low-dose prolonged infusion of gemcitabine. Patients and Methods: Eligible patients had non-small cell lung cancer in stage IIIB (wet) or IV, Karnofsky performance status 100 to 70 (Eastern Cooperative Oncology Group 0 -2), measurable disease, were chemonaïve and fulfilled the standard criteria for chemotherapy. In arm A (standard treatment), gemcitabine was given at 1250 mg/m 2 in 20 to 30 minutes and in arm B (prolonged infusion) at 250 mg/m 2 in 6 hours infusion. All patients received gemcitabine on days 1 and 8 and cisplatin at 75 mg/m 2 on day 2 of a 3-week cycle for four cycles, followed by two cycles of gemcitabine as monotherapy. Results: A total of 249 patients (188 men and 61 women, median age 58 years) were randomized between arm A (125 patients) and arm B (124 patients). Adenocarcinoma (53.9%) was the predominant histologic type; 92% of patients were in stage IV. The two groups were balanced for prognostic factors; however, group A had fewer patients with significant weight loss and no patient with lung cancer as a second malignancy or after radiotherapy for brain metastases. Grade 3 or greater toxicity was rare: anemia in 0.8 and 3.2%, neutropenia in 21.6 and 22.6%, thrombocytopenia in 0 and 1.6%, and nausea/vomiting in 4 and 8.1% for arms A and B, respectively. Alopecia was seen in 54.5% of patients in arm B, as compared with 9.7% in arm A. No patient died of treatment-related toxicity. During cycle 5, 47.7% of patients in arm A and 60.7% in arm B reported improved well-being, as compared with the status before chemotherapy. Patients in arm A had no complete remission, 32.8% partial responses, 48% minimal responses or stable disease, 13.6% progressions, and 5.6% were not evaluable. For arm B, the corresponding figures are as follows: complete remission 0.8%, partial responses 46% (for overall response rate of 46.8%), minimal responses or stable disease 36.3%, progression 12.1%, and not evaluable 4.8%. Median progression-free survival was 5.5 and 6.0 months, median overall survival was 10.1 and 10.0 months, and 1-year survival was 46.6 and 41.1% for arms A and B, respectively. For the 71 patients with squamous carcinoma, arm B seems superior to arm A, as seen by the higher overall response rate (51.3 versus 35.5%), longer median progression-free survival (6.2 versus 4.9 months), and longer median survival (11.3 versus 8.5 months). However, because of the small number of patients, these differences did not reach the level of statistical significance. Conclusion: In the treatment of advanced non-small cell lung cancer, gemcitabine in low dose in prolonged infusion in combination with cisplatin has low toxicity and has activity comparable with gemcitabine in higher dose in standard brief infusion. Low-dose gemcitabine may be preferred for incurable cancer among economically deprivileged patients. In addition, apparent superior activity against squamous carcinoma opens new perspectives and deserves further research.
G emcitabine (usually in combination with a platinum compound) is among the standard drugs for the treatment of a variety of tumors, including non-small cell lung cancer (NSCLC). For the usual 20-to 30-minute infusion (dose rate 40 -60 mg/m 2 /min) and for the moderately prolonged infusion at dose rate 10 mg/m 2 /min, the maximumtolerated dose (MTD) is 1500 mg/m 2 or even higher. 1,2 When applied either in brief infusion or in moderately prolonged infusion at 10 mg/m 2 /min, the activity and the toxicity profile of gemcitabine are not superior to standard brief infusion. Therefore, several recent trials concluded that no further research of moderately prolonged gemcitabine is warranted. [3] [4] [5] By contrast, MTD falls significantly with lower dose rates of infusion of gemcitabine. With infusions lasting for 3, 6, or 24 hours, MTD falls to 450, 250, and 180 mg/m 2 , respectively. 6 -9 The explanation for this phenomenon lies in the saturation of deoxycytidine kinase, which occurs during 30-minute infusion. 10, 11 This enzyme is needed for conversion of gemcitabine into its active form gemcitabine-triphosphate. Although short infusion of a relatively high dose leaves most of the drug unmetabolized, prolonged infusion leads to higher intracellular concentration of the active metabolite. 12 Consequently, a lower dose is needed for a comparable activity.
Several phase I and phase II clinical trials have shown significant antitumor activity of gemcitabine in low dose in long infusion. The spectrum of diseases includes cancers of the lung, breast, pancreas, gallbladder, bladder, sarcomas, refractory leukemias, and refractory Hodgkin's disease. 8, [13] [14] [15] [16] [17] [18] [19] [20] Although promising experience has been reported, most trials were small and included heavily pretreated patients. Thus, both the activity and toxicity of gemcitabine in low dose in long infusion remain unclear.
As for the lung cancer, our group reported favorable experience with gemcitabine in long infusion in combination with cisplatin for advanced NSCLC. 21 In a phase I to II trial, chemonaive patients with advanced NSCLC received gemcitabine in escalating doses from 130 mg/m 2 to 170, 210, and 250 mg/m 2 in 6 hours, combined with cisplatin at 75 mg/m 2 . The mild toxicity, objective response rate of 46%, and median survival of 9.5 months allowed us to conclude that this treatment has activity at least comparable with the standard brief infusion of a much higher dose of the drug.
Recently, two other phase II trials also presented a similar favorable experience with prolonged infusion of gemcitabine and cisplatin for advanced NSCLC. A group from Nanchang, China applied gemcitabine at 250 mg/m 2 /6 hr on days 1 and 8 and cisplatin at 75 mg/m 2 on day 2. Low toxicity and a 39.3% response rate were reported. 22 A group from Mumbai applied gemcitabine at 350 mg/m 2 (days 1 and 8) and carboplatin at area under the curve 5 also given on day 1. They concluded that treatment with low-dose prolonged infusion of gemcitabine and standard carboplatin is effective in advanced-stage NSCLC, has low toxicity, is safe even in elderly patients, and can result in substantial saving in chemotherapy cost. 23 We here present experience from a phase II randomized clinical trial, comparing standard brief infusion of gemcitabine with the low-dose prolonged infusion, both in combination with cisplatin for patients with advanced NSCLC. Primary objectives of the trial were progression-free survival and overall survival; secondary objectives were toxicity, response rate, and quality of life.
PATIENTS AND METHODS

Eligibility Criteria
Eligible patients had microscopically confirmed NSCLC; had stage IIIB with pleural effusion or stage IV; Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; were chemonaive; had no urgent local problems such as superior vena cava syndrome, symptomatic brain metastases, or severe bone pain; had measurable disease at a nonirradiated site; had hemoglobin above 100 g/liter and neutrophils, thrombocytes, creatinine clearance, and bilirubin within normal limits; had no significant cardiovascular or neurologic comorbidity or active infection; and gave written consent to be enrolled in clinical trial. Previous surgery and/or radiotherapy for another cancer were allowed for patients in remission lasting more than 3 years.
If the patient was treated previously by radiotherapy, all acute radiation-related toxicity should have been resolved; the minimal interval to the beginning of chemotherapy was 3 weeks for total dose more than or equal to 30 Gy or 10 days for total dose less than 30 Gy. Patients after surgery and radiotherapy for brain metastases were eligible if they met other eligibility criteria and were free of major neurologic symptoms.
Initial Diagnostics
All patients had their standard diagnostics for lung cancer, including blood tests, imaging with chest radiograph, chest and upper abdominal computed tomography, abdominal ultrasound, bone scan, bronchoscopy, and appropriate tissue diagnostics. Precise measurement of the initial maximal tumor diameter within 3 weeks before treatment was mandatory. In the absence of neurologic symptoms, the brain was not screened for metastatic disease. Positron emission tomography-computed tomography was not available.
ECOG scale was used to assess the initial performance status. Weight loss during the last 3 months and smoking status were recorded.
Registration and Randomization
Patients were registered for the trial with e-mail to data manager of the unit of clinical research. Randomization between arms A (standard chemotherapy) and B (low-dose gemcitabine in long infusion), 1:1, was done using a computer-generated sequence of random numbers. After registration, all patients were considered as participating in the trial, regardless of the treatment which they actually received.
Treatment
Arm A-Standard Treatment
Gemcitabine 1250 mg/m 2 in 20 to 30 minutes infusion on days 1 and 8; Cisplatin 75 mg/m 2 with appropriate hydration and antiemetics on day 2; Cycle was repeated on day 22.
Arm B-Prolonged Infusion
Gemcitabine 250 mg/m 2 in 6 hours on days 1 and 8; Cisplatin and cycle duration as above. After four cycles, patients not in progression continued with two additional cycles of gemcitabine as monotherapy, delivered either as brief infusion (arm A) or prolonged infusion (arm B).
Treatment Modification and Supportive Treatment
In case of grade 1 (National Cancer Institute-common toxicity criteria, version 2.0) neutropenia and/or thrombocytopenia, the dose of gemcitabine was reduced to 75%; the drug was omitted with grade 2 or greater neutro/thrombocytopenia. Cisplatin was reduced to 80% in case of grade 1 nephrotoxicity and was omitted in case of a higher level of nephrotoxicity and/or grade 3 nausea or vomiting.
All treatment was delivered in day hospital. Standard hydration and antiemetics were given. Because our previous phase I-II trial indicated a possible increased risk for thromboembolic events after low-dose gemcitabine in long infusion, all patients in both treatment arms received low molecular weight heparin for the duration of the active treatment.
Evaluation for Response, Quality of Life, and Toxicity
During cycles 3 and 5, imaging was repeated to assess tumor response according to RECIST, using the same method as during initial imaging.
ECOG performance status was recorded monthly. During cycles 3 and 5, quality of life was evaluated by the European Organization for Research and Treatment of Cancer Lung Cancer Symptom Scale-observer and patient scale. In addition, we used our own simplified scale for assessment of quality of life: How do you feel in comparison with your feeling prior to treatment?
1. much worse; 2. worse; 3. about the same; 4. better; 5. much better.
Side effects of treatment were assessed according to the National Cancer Institute-common toxicity criteria, version 2.0.
Follow-Up, Evaluation for Progression, and Second-Line Treatment
After treatment, patients were invited to follow-up visits every second month during the first year and at longer intervals thereafter. In addition to clinical examination and blood tests, chest radiograph or other appropriate imaging was repeated to assess the site(s) of active disease.
In case of progression, every effort was made toward effective palliation of the leading symptoms. Additional systemic treatment was always discussed with the patient and at the tumor board. Treatment was never prolonged at the expense of an unbearable quality of life.
Ethical Issues and Statistical Considerations
The investigators strictly followed recommendations of the Declaration of Helsinki (1964, with later amendments) and of the European Council Convention on Protection of Human Rights in Bio-Medicine (Oviedo 1997). The protocol was approved by the Institutional Review Board (Institute of Oncology, Ljubljana) and by the National Committee for Medical Ethics, Ministry of Health, Republic of Slovenia.
The data were described as the absolute numbers with corresponding relative frequencies. A 2 test was used to examine the difference in the prognostic factors between arms. Progression-free survival has been defined as the time from the date of randomization to the date of disease progression or death (two events, whichever occurred first). Median progression-free and overall survivals were estimated by Kaplan-Meier survival curves; groups were compared by the log-rank test. The effects of the treatment modality on the survival were analyzed by the Cox model, allowing us to control the results for age, gender, histologic type, and weight loss. A p value less than 0.05 was considered statistically significant. Statistical analysis was performed using the SPSS software package (version 16.0).
Because of the limited number of patients in a singleinstitution trial, we could not aim at a statistically significant difference in any of the observed parameters. Rather, the trial size of 250 patients was defined according to the expected accrual of patients in our institution within 3 years. Although the limited size and low power of such a randomized phase II trial rarely leads to a statistically clear comparison, it may offer a valuable orientation for further clinical research. 24 
RESULTS
Recruitment of Patients
Between December 2003 and October 2006, all eligible patients seen at the Institute of Oncology, Ljubljana, were invited to participate, and more than 90% consented to join the trial. In total, 250 patients were recruited in the trial. One patient (initially randomized to arm B and currently still alive) was later found to have metastatic breast cancer with endobronchial extension of a metastasis, rather than primary NSCLC, and was therefore excluded from all further analyses. This leaves us with 125 patients in arm A and 124 patients in arm B.
As expected, men (188 or 75.5%) predominated women (61 or 24.5%). Median age was 58 years, with a range of 40 to 79 years. Most patients were smokers; however, 31 patients (12.4%) were never smokers and an additional 65 patients (26.1%) have given up smoking more than 3 years before current disease. Six patients, all of them randomized to treatment B had previous other cancer: three were after treatment for head and neck cancer, two had cervical cancer, and two others had non-Hodgkin's lymphoma of the stomach and pheochromocytoma.
The distribution of patients between arms A and B according to demographics and to prognostic factors is shown in Table 1 . There was no statistical significant difference between arms in prognostic factors shown in Table 1 except for significant difference in previous cancers ( 2 p ϭ 0.013) and percentage of weight loss ( 2 p ϭ 0.015). Adenocarcinoma (137 patients or 55.0%) was the most common histologic type, followed by squamous carcinoma (28.5%), NSCLC of poorly differentiated or unspecified type (10.8%), and large-cell carcinoma (5.2%).
Only six patients had previous thoracic surgery. Thus, most patients (243 or 97.6%) had active disease at the primary site and/or regional lymph nodes. Only 20 patients (8.0%) had stage IIIB disease confined to primary tumor, pleura, and/or pericardium. Among 92.0% of patients with metastatic disease, distant lung metastases (52.2%) were the most common site, followed by bone (26.1%), suprarenals (18.9%), distant lymph nodes and soft tissues (16.1%), and liver (15.7%). Three patients (1.2%) had previous surgery and radiotherapy for brain metastases.
Distribution of patients among the two treatment groups according to histology, stage, active sites of disease, and initial hemoglobin and C-reactive protein levels is given in Table 2 .
Treatment
After registration and randomization into arm A and before any treatment, a man aged 53 years developed symptoms of brain metastases. This patient was treated with radiotherapy to the brain and later continued treatment with gemcitabine as monotherapy. All other patients received at least one cycle of chemotherapy according to the protocol.
Five or all six cycles of chemotherapy were given to 97 (77.6%) patients in arm A and to 97 (78.2%) patients in arm B. The reasons for early termination of the treatment were tumor progression (11.2 and 8.9% for arms A and B, respectively) and toxicity, deterioration of patient's performance status, or patient's refusal (8.8 and 10.5% for arms A and B, respectively).
Toxicity
In general, both treatments were tolerated well. Grade 3 or greater hematologic toxicity was rare: anemia in 0.8 and 3.2%, neutropenia in 21.6 and 22.6%, and thrombocytopenia in 0 and 1.6% for arms A and B, respectively. No patient had febrile neutropenia. Thrombocytosis was common and reached levels above 800 ϫ 10 9 /liter in 32 (12.8%) patients (Table 3) .
Of the nonhematologic toxicity, grade 2 nausea and/or vomiting were common (19.2% in arm A and 22.6% in arm B). Grade 3 nausea and/or vomiting were seen in 4.0 and 8.1% 2  53  44  3  1  3  4  0  1  Neutropenia  2  30  31  3  2 1  2 6  4  6  2  Thrombocytopenia  2  0  3  3  0  2  Thrombocytosis  501-800  69  64  801-1000  13  10  Ͼ1001  5  4  Median  592  544  Maximum  1386  1196 for arms A and B, respectively. Grade 3 nephrotoxicity was not seen, and a single patient in arm B had transient grade 4 nephrotoxicity.
Grade 2 alopecia was rare in the standard arm (9.7%) and significantly more common in patients treated with long infusion of gemcitabine (54.5%, p Ͻ 0.01).
Response to Treatment and Assessment of Quality of Life
Patients in arm A had no complete remission: 32.8% partial responses; 48% minimal responses or stable disease; 13.6% progressions; and 5.6% not evaluable.
A single patient in arm B had pathologically documented complete response, as proven by resection of a solitary bone metastasis and of the primary lung tumor. This patient remained in remission for 49 months when brain metastases were diagnosed. Partial responses were seen in 46%, and overall response rate was 46.8%. Minimal response or stable disease was seen in 36.3%, progression in 12.1%, whereas 4.8% were not evaluable. Table 4 presents data on response to treatment and assessment of performance status and patient's self-assessment of quality of life during the fifth cycle of chemotherapy. There is a trend toward better responses, higher performance status, and higher quality of life in arm B; still, the differences do not reach the level of statistical significance.
Data from European Organization for Research and Treatment of Cancer Lung Cancer Symptom Scale questionnaire were incomplete and were not further analyzed.
Progression-Free Survival, Second-Line Treatment, and Overall Survival
Median progression-free survival was 5.5 and 6.0 months for arms A and B, respectively (Figure 1 ). The progression-free hazard of arm B patients was 0.848 compared with that of arm A patients (p ϭ 0.211). On progression, most patients were treated with palliative radiotherapy and supportive care. Any kind of secondline systemic treatment was offered to 21.6% of patients, with similar figures for both treatment arms.
No patient was lost to follow-up. Median overall survival was 10.1 and 10.0 months, and 1-year survival was 46.6 and 41.1% for arms A and B, respectively. The survival hazard of patients randomized to the arm B was 0.977 compared with that of arm A patients (p ϭ 0.861).
Subanalysis According to Histologic Type
Among 71 patients with squamous cell carcinoma, patients were equally distributed between arms A (32 patients) and B (39 patients) according to prognostic factors (data not shown). In squamous carcinoma, arm B seems superior to arm A, as seen by the higher overall response rate (51.3 versus 35.5%), longer median progression-free survival (6.2 versus 4.9 months; log rank p ϭ 0.182; Figure 2 ), improved well-being during cycle 5 as compared with the status before chemotherapy (64.1 versus 43.7%), and longer median survival (11.3 versus 8.5 months; log rank p ϭ 0.406). However, because of the small number of patients, these differences did not reach the level of statistical significance.
DISCUSSION
This is the first randomized clinical trial to compare gemcitabine in low dose in prolonged infusion with the same drug given in much higher dose in short infusion. So far, no such comparison has been made. All reports on phase II trials of low-dose gemcitabine in prolonged infusion therefore lacked a proper perspective in relation to the main stream of clinical research, where brief infusion of gemcitabine in a higher dose is an established standard.
Our trial included 92% of patients in stage IV and did not exclude the elderly, those in performance status 2, those with another malignancy in their medical history or patients after treatment for brain metastases. Although the two groups were balanced for most prognostic factors, group B included more patients with significant weight loss, fewer patients with squamous histology, all six patients after treatment for another malignancy, and all three patients after surgery and radiotherapy for brain metastases. Despite this imbalance, response rates, performance status, and quality of life during cycle 5 and progression-free survival were slightly (albeit not significantly) in favor of the low-dose long infusion group; survival for both groups was identical. Thus, it seems that treatment with gemcitabine in low dose in long infusion is not inferior to standard brief infusion of the drug in a much higher dose.
For both arms, toxicity was low. Although moderate anemia was common, very few patients in both treatment arms had significant neutropenia or thrombocytopenia. Thrombocytosis was common but without significant consequences, possibly because of routine use of low molecular weight heparin. Alopecia was significantly more common in the low-dose long infusion group. Some oncologists argue that cost of treatment should not be considered in our medical decisions, but we do not share that view. Even in developed countries, some patients have to pay for their treatment; the situation is worse in developing countries where social solidarity in health care is virtually nonexistent. Lung cancer is often a disease of the lower social class, 25 and the incidence of lung cancer in developing countries is rapidly increasing. 26 Besides, even if the treatment is paid by some kind of health insurance, reducing costs for cancer drugs may spare resources for other needs such as prevention, improved early diagnostics, or palliative treatment. For all these reasons, we believe that low-dose gemcitabine in prolonged infusion is a valuable alternative to the standard chemotherapy of NSCLC. However, it is clear that expenses for the drug are not the only difference when comparing standard and low-dose gemcitabine. Costs for infusion systems and for the day hospital, and the burden of long infusion and of alopecia for incurably ill patients should also be considered.
During the past decade and, in particular, after publication of the ECOG 1594 trial, 27 many consider that all chemotherapy regimes for NSCLC are virtually identical; any effort to find a more effective combination of the existing drugs may be futile. However, a recent large trial compared combinations of gemcitabine-cisplatin and pemetrexed-cisplatin and showed a significant advantage with pemetrexed for nonsquamous and with gemcitabine for squamous histology 28 . It is now clear that particular types of lung cancer show different sensitivity not only to targeted drugs but also to classic cytotoxic agents. Albeit not reaching statistical significance, experience from our trial on improved efficacy of gemcitabine in long infusion for patients with squamous cell carcinoma deserves further study. We know that these patients rarely benefit from targeted therapy and are considered resistant to pemetrexed. Therefore, our experience is one of the few potential advancement for patients with the squamous type of lung cancer. A larger study on patients with lung and possibly with other cancers of the squamous type may be considered.
